F-14413
In-game article clicks load inline without leaving the challenge.
F-14413, also known as 5-fluoro-methoxyidazoxan, is an α2-adrenergic receptor antagonist or inverse agonist which was under development for the treatment of Alzheimer's disease and Parkinson's disease in France but was never marketed. It is a derivative of idazoxan. The drug's route of administration was unspecified. It is said to be potent and highly selective as an α2-adrenergic receptor modulator. F-14413 was under development by Pierre Fabre. It reached the preclinical research stage of development prior to its discontinuation. F-14413 was first described in the scientific literature by 2001, while its latest developmental update was in 2003.